April 16 (Reuters) - Merck & Co's immunotherapy Keytruda plus chemotherapy significantly improved overall survival in newly-diagnosed patients with advanced non-small cell lung cancer in a closely-watched study, cementing its lead position over Bristol-Myers Squibb Co and others in the most lucrative oncology market.


00


Reuters

Latest News

CNBC: Trump, Macron to face differences on Iran, trade, as French visit begins

CBS: A scary retirement expense that shouldn't terrify you

CNN: Land of Fire opens up to visitors

CNN: Maria Sharapova wants 'big stage winning feel again'

BBC: Report recommends closure for St Margaret's Primary in Hawick

Daily Mail: Doctor is suspended after mother-of-six dies 'after she was turned away'

Daily Mail: Libya examines Total-Marathon purchase, casting doubt...

Daily Mail: Ryan Shawcross admits Stoke City are 'sleepwalking' towards relegation

FOX: Spain resumes controversial exhumations near Franco's tomb

Daily Mail: Video: School girl dance group 'Rise' discuss BGT performance on Lorraine

Daily Mail: Terror suspect jailed for 20 years over attempted...

Daily Mail: Body of Briton reported missing on Hamburg trip found...

Daily Mail: WHO STARTED TFL'S THOUGHT OF THE DAY TREND? 

Reuters: Russia, China to obstruct U.S. attempt to sabotage Iran nuclear deal: TASS

FOX: Britain's Duchess of Cambridge in labor with third child

Daily Mail: Britain’s Got Talent: Manchester bomb survivor Hollie Booth insists she's 'getting better every day'

Daily Mail: Russia, China to obstruct U.S. attempt to sabotage Iran...

Daily Mail: WHAT ARE CLOTHES MOTHS AND HOW CAN YOU STOP THEM INFESTING YOUR HOME? 

Daily Mail: Robin van Persie celebrates after Dutch Cup triumph

Daily Mail: Merseyside police on alert ahead of Liverpool's Champions League semi-final tie with Roma

Daily Mail: Clothes moths favour posh southern homes

CNN: Sharapova wants 'big stage winning feel again'

Reuters: Facebook's hidden data haul troubles German cartel regulator